A Recombinant Enolase-Montanide™ PetGel A Vaccine Promotes a Protective Th1 Immune Response against a Highly Virulent Sporothrix schenckii by Toluene Exposure

Téllez-Martínez, Damiana; Portuondo, Deivys Leandro; Loesch, Maria Luiza de Aguiar; Batista-Duharte, Alexander; Carlos, Iracilda Zeppone

doi:10.3390/pharmaceutics11030144

Cited by 13 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-Gp70 is one of the antibodies that has been widely recognized as playing protective role against S. schenckii and S. brasiliensis infection (21,22). Recently, anti-enolase antibodies were also characterized involved in antifungal responses in S. schenckii and S. brasilensis infected mice (23,24). In human sporotrichosis, the IgG, IgM and IgA antibodies were detected in all of the clinical forms (25).…”

Section: Introductionmentioning

confidence: 99%

Th2 Biased Immunity With Altered B Cell Profiles in Circulation of Patients With Sporotrichosis Caused by Sporothrix globosa

Yao

Song

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Th2 Biased Immunity With Altered B Cell Profiles in Circulation of Patients With Sporotrichosis Caused by Sporothrix globosa

Yao

Song

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

“…With these initial results, an experimental study to evaluate the effect of the administration of anti-Foxp3 ASO on the immunogenicity of an experimental vaccine against Sporothrix schenckii previously developed in our laboratory [ 27 , 28 ] was carried out. We used the same experimental design previously described but including the anti-Foxp3 ASO within the formulation to determine its effect on the specific immune response.…”

Section: Resultsmentioning

confidence: 99%

Foxp3 Silencing with Antisense Oligonucleotide Improves Immunogenicity of an Adjuvanted Recombinant Vaccine against Sporothrix schenckii

Batista-Duharte

Sendra

Herrero

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Background: In recent years, there has been great interest in developing molecular adjuvants based on antisense oligonucleotides (ASOs) targeting immunosuppressor pathways with inhibitory effects on regulatory T cells (Tregs) to improve immunogenicity and vaccine efficacy. We aim to evaluate the immunostimulating effect of 2′OMe phosphorothioated Foxp3-targeted ASO in an antifungal adjuvanted recombinant vaccine. Methods: The uptake kinetics of Foxp3 ASO, its cytotoxicity and its ability to deplete Tregs were evaluated in murine splenocytes in vitro. Groups of mice were vaccinated with recombinant enolase (Eno) of Sporothix schenckii in Montanide Gel 01 adjuvant alone or in combination with either 1 µg or 8 µg of Foxp3 ASO. The titers of antigen-specific antibody in serum samples from vaccinated mice (male C57BL/6) were determined by ELISA (enzyme-linked immunosorbent assay). Cultured splenocytes from each group were activated in vitro with Eno and the levels of IFN-γ and IL-12 were also measured by ELISA. The results showed that the anti-Eno antibody titer was significantly higher upon addition of 8 µM Foxp3 ASO in the vaccine formulation compared to the standard vaccine without ASO. In vitro and in vivo experiments suggest that Foxp3 ASO enhances specific immune responses by means of Treg depletion during vaccination. Conclusion: Foxp3 ASO significantly enhances immune responses against co-delivered adjuvanted recombinant Eno vaccine and it has the potential to improve vaccine immunogenicity.

show abstract

“…The adjuvanted vaccine induced a strong, specific Th1 response and protective immunity against challenge with either wild-type or toluene-adapted S. schenckii in Balb/c mice. These studies highlight the role of the adjuvant PGA in driving the increasing of anti-Sporothrix immunity and as the key component in vaccine efficacy [50].…”

Section: Vaccine and Immunotherapymentioning

confidence: 95%

Advances in Vaccine Development Against Sporotrichosis

Almeida

2019

Curr Trop Med Rep

View full text Add to dashboard Cite

Purpose of Review To review recent data about the study of the immune response in sporotrichosis and recent progress in the development of an effective human and feline vaccine. Recent Finding The cell wall of Sporothrix is an important source of antigens with the potential to develop vaccines. A major candidate is a 70-kDa glycoprotein (gp70). Our group developed a model of sporotrichosis treatment using the monoclonal against gp70 (mAbP6E7) with good results. We also recently developed a humanized antibody, mAbP6E7, that increased phagocytosis in human monocytes and reduced the fungal burden in a murine model of sporotrichosis. The other importance the study demonstrated is the protective capacity of an enolase-based vaccine and Montanide™ Pet Gel A (PGA) as an adjuvant against S. schenckii. The use of an immunoproteomic approach demonstrated the efficacy of three peptides as a vaccine to promote a protective immune response against sporotrichosis that aid the development of novel therapeutic approaches against fungal infections. Summary Several diseases have been eradicated with the use of vaccines, but the development of vaccines against fungal infections in humans and animals remains a challenge, in part due to a lack of knowledge about the mechanisms of protective immunity against fungal infections and the genetic complexity of fungi. In this review, we discuss recent advances in vaccine development against sporotrichosis.

show abstract

A Recombinant Enolase-Montanide™ PetGel A Vaccine Promotes a Protective Th1 Immune Response against a Highly Virulent Sporothrix schenckii by Toluene Exposure

Cited by 13 publications

References 42 publications

Th2 Biased Immunity With Altered B Cell Profiles in Circulation of Patients With Sporotrichosis Caused by Sporothrix globosa

Th2 Biased Immunity With Altered B Cell Profiles in Circulation of Patients With Sporotrichosis Caused by Sporothrix globosa

Foxp3 Silencing with Antisense Oligonucleotide Improves Immunogenicity of an Adjuvanted Recombinant Vaccine against Sporothrix schenckii

Advances in Vaccine Development Against Sporotrichosis

Contact Info

Product

Resources

About